Tag: Shots

  • Moderna says its new ‘bivalent’ vaccine shows promise : Shots

    Moderna says its new ‘bivalent’ vaccine shows promise : Shots

    A overall health care employee prepares the current COVID vaccine booster photographs from Moderna in February. The company states a bivalent vaccine that brings together the unique pressure with the omicron strain is the guide applicant for a tumble vaccination marketing campaign.

    Bloomberg/Bloomberg through Getty Visuals


    disguise caption

    toggle caption

    Bloomberg/Bloomberg by means of Getty Visuals


    A well being treatment worker prepares the present-day COVID vaccine booster shots from Moderna in February. The enterprise claims a bivalent vaccine that combines the unique pressure with the omicron strain is the direct candidate for a drop vaccination campaign.

    Bloomberg/Bloomberg through Getty Photographs

    The pharmaceutical business Moderna declared Tuesday that a new variation of the firm’s COVID-19 vaccine appears to offer much better, more time-long lasting defense versus variants of the virus than the unique vaccine.

    Preliminary final results from a study tests a vaccine that targets the two the primary strain of the virus and the beta variant — a so-called “bivalent” vaccine — appears to make higher amounts of antibodies for months that can neutralize the virus.

    “We imagine that these results validate our bivalent tactic,” stated Stéphane Bancel, Moderna’s chief govt officer, in a information launch.

    Bancel added that another bivalent vaccine that brings together the first pressure with the omicron pressure “continues to be our lead prospect” for a tumble vaccination campaign aimed at shielding individuals from a wintertime surge. Final results from the tests of that model are anticipate later this spring, according to Moderna.

    “We imagine that a bivalent booster vaccine, if authorized, would create a new tool as we carry on to respond to emerging variants,” Bancel claimed.

    The research has not still been reviewed by unbiased experts and developed blended reactions from outdoors specialists.

    “This paper is a ‘proof of principle’ that supports the concept of a bivalent mRNA vaccine,” wrote Nathaniel Landau, a microbiologist at New York University, in an e-mail to NPR. But Landau agreed a omicron-distinct model would almost certainly be the most handy.

    Dr. Jesse Goodman, a former prime Foods and Drug Administration scientist now at Georgetown University, agreed the effects are encouraging. But he also noted the tactic demands to be verified by further investigation.

    “Other matters could be at engage in in earning the bivalent booster search superior,” Goodman wrote in an electronic mail to NPR.

    John Moore, an immunologist at Weil Cornell Medication, termed the benefits “unimpressive” in an email to NPR. “What is actually right here is unlikely to support the rollout of this form of bivalent vaccine — the gains would not justify the expense and headache.”

    Dr. Celine Gounder, an infectious ailment skilled at Kaiser Wellbeing News, said the company’s announcement “appears misleading” for the reason that it as opposed the antibodies from just two doses of the primary vaccine with a third dose of the new vaccine.

    Researchers are testing a number of new versions of Moderna’s and Pfizer’s vaccines to see if they provide broader defense again the omicron variant. Federal officers are hoping to see plenty of effects by afterwards this spring to give firms plenty of time to create sufficient vaccines for a different spherical of photographs in the slide, when immunity from past vaccination and infections may perhaps be waning and one more surge could be looming.

  • FDA advisers voice support for reformulated COVID boosters : Shots

    FDA advisers voice support for reformulated COVID boosters : Shots

    A pop-up clinic inside of Los Angeles Intercontinental Airport provided free vaccinations and boosters for holiday break travelers final December. A new spherical of vaccinations might be wanted in advance of upcoming wintertime.

    FREDERIC J. BROWN/AFP through Getty Pictures


    cover caption

    toggle caption

    FREDERIC J. BROWN/AFP by using Getty Visuals


    A pop-up clinic inside Los Angeles Worldwide Airport available totally free vaccinations and boosters for holiday break tourists last December. A new spherical of vaccinations may perhaps be needed right before up coming wintertime.

    FREDERIC J. BROWN/AFP by using Getty Photographs

    In a daylong digital conference, a panel of professionals advising the Food stuff and Drug Administration arrived out in general guidance of endeavours to create new COVID-19 vaccines tailored to variants.

    The committee was not requested to vote on any particular tips to the agency but as a substitute mentioned the framework for creating selections about when to change the viral strain or strains utilised for potential vaccines, such as boosters.

    “I feel we are in uncharted territory for the reason that with SARS-CoV-2 a large amount of items have happened that have never transpired before,” stated Dr. Arnold Monto, professor emeritus at the College of Michigan and acting chair of the committee.

    It really is probably the panel will reconvene in May well or June to consider a far more unique proposal for reformulation of COVID-19 vaccines.

    The process utilised to tweak annual flu vaccines to match circulating strains is a single model that may possibly notify the approach for COVID-19, but there are even now many unknowns about how the coronavirus may perhaps transform and stark distinctions amongst the influenza virus and SARS-CoV-2.

    Drop goal for new type of booster

    The crucial thing to consider is no matter whether a variant-distinct booster need to be built out there this slide. The rise of the omicron variant, and these days a subvariant known as BA.2, has sharpened the query. The vaccines now in use in the U.S. are centered on the sort of the virus that circulated at the starting of the pandemic and are much less effective from some later on strains.

    “Despite the fact that we have seen a major decline in the variety of COVID-19 cases in the place, the virus proceeds to circulate and it will continue on to do so and will possibly cause waves of an enhanced quantities of cases,” said Dr. Peter Marks, head of the FDA’s Heart for Biologics Analysis and Investigation, at the start off of the assembly. “This is of notably problem as we head into the slide and winter season period.”

    Marks also mentioned that the coronavirus will have had a further much more time to evolve by the time fall comes in the U.S.

    In the course of the morning session, Israeli researchers presented data on the waning safety of a single booster dose of the Pfizer-BioNTech vaccine and the elevated protection of a next booster from infections, which was fleeting, and significant health issues, which was for a longer time long lasting. The rapid spread of the omicron variant contributed to the decline in security from immunization with 1 booster.

    Israeli authorities accepted a second booster in early January for persons 60 and more mature and other individuals at high threat or who labored in health care. The Israeli experience contributed to the FDA’s decision in late March to authorize a second booster dose for persons 50 and older as well as for other people today with compromised immune programs.

    Predicting viral evolution is ‘quite difficult’

    Rapid genetic adjustments in the coronavirus are driving its ability to evade the immune response from vaccination and prior bacterial infections. The continuing changes complicate choices about which strains to contain in new vaccines.

    “In normal, from every thing we’ve witnessed, we need to count on a lot of evolution heading forward, and we really should have methods to maintain up with this evolution in terms of our vaccination platforms,” stated Trevor Bedford, who studies viral evolution at the Fred Hutchinson Cancer Centre in Seattle.

    He mentioned that predicting where by the virus is headed is “very challenging.” The coronavirus has been evolving have to faster than the flu. Considerable new variants of the coronavirus have emerged in just months alternatively of the years it can usually takes for the flu to make these jumps.

    Based on the rate of the coronavirus’ evolution so considerably and uncertainty about what lies in advance, Bedford estimates a dangerous new variant like omicron could arise inside about a calendar year and a half or maybe not for extra than a ten years.

    There is just not significantly time to make vaccine alterations in time for an immunization press this slide. “If you might be not on your way to a scientific demo by the beginning of May possibly, I imagine it really is going to be really complicated to have enough product throughout manufacturers to meet up with desire,” said Robert Johnson, deputy assistant secretary of the federal Biomedical Highly developed Study and Advancement Authority.

    FDA’s Marks acknowledged that there is a compressed timetable for determining upon booster make-up, but there may well be “some wiggle space” that could allow for for a resolve in May perhaps or June.

    There is certainly a whole lot using on the choice. “We basically can not be boosting people as regularly as we are,” Marks stated, adding that the 2nd booster dose authorized not long ago by Fda was “a stopgap measure” to support safeguard the most susceptible persons.

    The intention for a reformulated booster someday later on this 12 months, Marks explained, would be to “improve yet again in order to safeguard from a wave that could appear at the time we are at optimum risk.”

    In closing remarks, committee chair Monto explained, “We’d like to see an yearly vaccination equivalent to influenza but comprehend that the evolution of the virus will dictate how we’ll reply.”

    Rob Stein contributed to this report.

  • New laws say patients can have visitors even in an outbreak : Shots

    New laws say patients can have visitors even in an outbreak : Shots

    Mary Daniel took a dishwasher job at her husband’s Florida memory care facility to see him during the initial coronavirus lockdown. She has been fighting for visitation rights ever since.

    Tiffany Manning for NPR


    hide caption

    toggle caption

    Tiffany Manning for NPR


    Mary Daniel took a dishwasher job at her husband’s Florida memory care facility to see him during the initial coronavirus lockdown. She has been fighting for visitation rights ever since.

    Tiffany Manning for NPR

    Jean White’s mother has dementia and moved into a memory care facility near Tampa, Fla., just as coronavirus lockdowns began in the spring of 2020. For months, the family wasn’t allowed to go inside to visit.

    They tried video chats and visits from outside her bedroom window, but White said that just upset her mom, who is 87.

    White’s mother couldn’t grasp why she could hear familiar voices but not be with her loved ones in person.

    When the family was allowed in to see her, disruptions continued. White said the facility kept shutting down anytime a resident or staff member had the virus.

    KHN logo

    All the while, her mom’s memory was deteriorating.

    “You know it’s going to happen, but still, when it does. And when you haven’t — when you miss time that you thought you had,” White said, speaking haltingly and with emotion as she talked about her mother’s decline.

    Restrictions on visitation have relaxed in recent months, White said, but she questions whether protecting her mom from COVID-19 was worth the lengthy separation.

    “What anxiety, loneliness and confusion she must have had – I think I would have rather her seen her family,” she said.

    On March 11, the Florida Legislature passed a bill that will make it easier for people like White to see their loved ones in health facilities. Gov. Ron DeSantis is expected to sign it in the coming weeks. At least eight states have already passed similar laws, and several others have bills under consideration.

    Some laws, like those passed last year in New York and Texas, are specific to long-term care facilities. They allow residents to designate essential caregivers, also known as compassionate caregivers, who are allowed to visit regardless of whether there is a health crisis. Texans also added protections in their constitution.

    Other states including Arkansas, North Carolina and Oklahoma passed similar “No Patient Left Alone” acts that also guarantee visitor access to patients in hospitals.

    Hospitals and long-term care facilities set pandemic restrictions on visitors to protect patients and staffers from infection. But supporters of these news laws say they want to ease the restrictions because the rules may have harmed patients.

    An Associated Press investigation found that for every two residents in long-term care who died from COVID-19, another resident died prematurely of other causes. The report, published in late 2020, attributed some of those deaths to neglect. Other deaths, listed on death certificates as “failure to thrive,” were tied to despair.

    Even in regions of the U.S. with low rates of COVID, risk of death for nursing home residents with dementia was 14{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} higher in 2020, compared to 2019, according to a study published in February in JAMA Neurology.

    The researchers pointed to factors besides COVID infection that may have contributed to the increased mortality, such as less access to in-person medical care and community support services, and “the negative effects of social isolation and loneliness.”

    She took a kitchen job so she could see her husband

    When long-term care facilities and hospitals began closing their doors to family visitors, patient advocate Mary Daniel, from Jacksonville, Fla., was worried about what might happen to her husband, Steve, who has Alzheimer’s.

    “I promised him when he was diagnosed that I would be by his side every step of the way, and for 114 days I was not able to do that,” Daniel said.

    To get back inside, Daniel took a dishwashing job at her husband’s assisted living facility so she could see him.

    Daniel would work in the kitchen two nights a week, then after her shift go to his room. She’d help him change into his pajamas and lay beside him watching TV until he fell asleep.

    “That is really why I’m there, to be his wife, to hold his hand, so he feels that love,” said Daniel.

    Daniel has been fighting for visitor rights at the state and federal levels ever since. She’s a leader of Caregivers for Compromise, a coalition with thousands of members. She also served on a state task force that informed Florida’s decision to order long-term care facilities to reopen to families in the fall of 2020.

    “We understand that COVID kills, but we want to be sure everyone understands isolation kills too,” Daniel said.

    While the visitation laws open the doors, they also include provisions to protect patients and staff by directing facilities to establish infection-control measures that families must follow to enter. That could mean mask requirements or health screenings. In Florida, protocols for visitors cannot be more stringent than they are for staff, and vaccination status cannot be a factor.

    Also in Florida, facilities will be able to ban visitors who don’t follow the rules. That’s fine with advocates like Daniel.

    “I mean we’re not here beating down the door saying, ‘You can never kick us out and I’m going to be here as long as I want to,’” she said. “We want to protect their health, we want to be sure that everything is safe.”

    DeSantis, who appointed Daniel to the 2020 task force, was a vocal supporter of expanding visitor access.

    “COVID cannot be used as an excuse to deny patients basic rights, and one of the rights of being a patient, I think, is having your loved ones present,” DeSantis said at a news conference in February.

    Balancing the joy of visits with the risks of infection

    In November, the Centers for Medicare & Medicaid Services directed nursing homes to open their doors to visitors even amid COVID-19 outbreaks, so long as they screen visitors to see if they have tested positive or have symptoms of COVID-19.

    Hospitals and assisted living facilities are not regulated in the same way as nursing homes. Some health care industry leaders fear the new laws for hospitals and assisted living won’t provide operators the flexibility they need to respond to crises.

    Veronica Catoe, CEO of the Florida Assisted Living Association, says she represents facilities with varying capabilities to accommodate visitation. Some are large with private rooms and multiple common areas; others are single-family homes that just have a handful of residents.

    “These operators are trying to protect not only the loved one that wants a visit, but also the loved one that doesn’t want these outsiders coming in. They both have resident rights,” Catoe said.

    Florida’s legislation outlines various scenarios during which visitation must be allowed at all times. Those include if a patient is dying, struggling to transition to their new environment, or experiencing emotional distress, among other factors.

    Catoe said those situations aren’t always easy to define.

    “Is it the facility that makes that decision, is it the family that makes that decision, or is it the resident?” she asked. “And when they’re in conflict, who gets the deciding factor?”

    Relatives wanted more time with a dying loved one

    Mary Mayhew, president of the Florida Hospital Association, said the decision is also difficult for medical centers.

    “They are extremely reluctant to place restrictions on [visitor] access, and it has largely been done during this extremely unusual time period when we have had a virus — continue to have a virus — that we are often learning something new about every day,” Mayhew said.

    She added that people go to hospitals because they’re already sick or injured, which makes them vulnerable to infection.

    “There is significant risk of any of those patients getting exposed to, in this case COVID, might be brought in by a visitor,” Mayhew said.

    Families are vital to patient care, she said, and stressed that even during COVID surges and lockdown, hospitals have tried to get relatives in to visit, especially when patients were dying.

    Kevin Rzeszut says his family needed more.

    “By the time we saw him, I mean, he was gone. There was no consciousness left; he was on so many medications,” Rzeszut said. His father died at 75 from a bacterial infection in August of 2021, when Tampa hospitals were overwhelmed with patients sick with the delta variant.

    Rzeszut said he couldn’t visit his dad for nearly two weeks. When doctors told the family to come say their goodbyes, Rzeszut’s 11-year-old son went along.

    “I think the worst part for me was that my son got to see him, you know, just hooked up to a bunch of machines and totally out of it, like that was it, you know?” said Rzeszut, his voice breaking with emotion.

    He said the staff did the best they could.

    “The nurses and doctors, they can look at notes all day long, but they don’t know him, they haven’t spent 53 years with the man” the way his mother had, Rzeszut said. “She’d be more attuned to minor improvements or degradations. Maybe that’s a pipe dream, but it feels real.”

    Rzeszut said he supports measures to give families more access to their loved ones, so long as enforcing them doesn’t add more workload to an “already overburdened” health care system.

    What he really wishes, he said, is that more people would take COVID seriously so people didn’t need a law to visit their loved ones.

    This story comes from NPR’s health reporting partnership with WUSF and KHN (Kaiser Health News).

  • Vaccines show promise in reducing long COVID : Shots

    Vaccines show promise in reducing long COVID : Shots

    Reseach is showing that folks who are vaccinated, even with just one particular dose, are likely to have lessen premiums of lengthy COVID after catching the virus than all those who are unvaccinated.

    Justin Sullivan/Getty Photos


    disguise caption

    toggle caption

    Justin Sullivan/Getty Pictures


    Reseach is showing that individuals who are vaccinated, even with just a single dose, have a tendency to have decreased costs of prolonged COVID soon after catching the virus than people who are unvaccinated.

    Justin Sullivan/Getty Visuals

    The likelihood of even a gentle situation of COVID-19 turning into a very long-time period, debilitating clinical affliction is one particular of the biggest fears of Americans trying to navigate the pandemic, which is yet again having a transform as new data show the BA.2 subvariant is using hold in the U.S.

    Unfortunately, the only absolutely sure way to stay away from extensive COVID is not to capture the virus in the 1st put.

    But there is now a expanding overall body of investigation which is giving at the very least some reassurance for these who do close up finding contaminated — staying entirely vaccinated looks to considerably slice the possibility of later establishing the persistent signs that characterize prolonged COVID.

    Whilst many of the results are nevertheless preliminary, the handful of studies that have emerged in the previous 50 {fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} year are telling a fairly constant tale.

    “It may well not eradicate the indicators of extended COVID, but the protecting outcome looks to be very robust,” says epidemiology professor Michael Edelstein, of Bar-Ilan University in Israel, who’s studying lengthy COVID.

    Edelstein’s analyze was just one of these incorporated in a new analysis of the evidence on very long COVID and vaccination finished by the United kingdom Health Security Agency. That overview observed vaccinated persons are inclined to have lessen premiums of very long COVID immediately after an an infection than those who are unvaccinated.

    There is a managing list of theories about why persons get lengthy COVID. Everlasting tissue destruction from the infection, harm to blood vessels and the enhancement of microclots, a lingering viral reservoir in components of the overall body, or an autoimmune issue are some of the tips remaining explored in the investigate.

    But even without the need of a obvious sense of what is actually particularly driving prolonged COVID, there’s very good reason to believe that vaccines would assist guard in opposition to the problem, says Dr. Steven Deeks, a professor of medication at the University of California, San Francisco.

    You will find too much to handle proof that an individual who’s vaccinated has a lot less virus in their body for the duration of an infection, he states, “so it would make good feeling that the quantity of virus-connected difficulties around time would also be decreased.”

    Appears to be good… but how excellent?

    One particular of the ongoing difficulties with extended COVID investigation is simply just defining the condition — with every single analyze taking a little bit different techniques as to what signs and symptoms depend and how very long they want to final right after the first an infection.

    This inconsistency would make it hard to pull with each other a solitary estimate for how a great deal vaccines restrict very long COVID.

    Commonly, even though, Deeks says vaccinated men and women feel to have a 50{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} reduce normal risk of acquiring lengthy COVID than unvaccinated men and women. This is in the assortment of what many reports in the U.K., Israel and the U.S. have uncovered.

    Ideally, extensive COVID should not be calculated only a several months right after the preliminary an infection, he states. “A whole lot of men and women are nevertheless gradually obtaining superior, so you have to hold out at the very least 4 months to type of determine out irrespective of whether or not these indicators will persist.”

    The Israeli review, conducted by Edelstein and his colleagues, adopted quite a few thousand individuals who were unvaccinated, partly vaccinated and thoroughly vaccinated. Those people who tested favourable had been requested to self-report their signs and symptoms in between four and 8 months after their original infection.

    Contributors who had two or 3 doses of the vaccines ended up about 50{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} to 80{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} fewer probable to report seven of the 10 most typical signs, which include shortness of breath, headache, weak point and muscle pain.

    Edelstein suggests these benefits are not essentially surprising, since they are suitable with other modern reports. “It gives us a very little bit of reassurance that if you’re vaccinated, you lessen your possibilities of prolonged COVID rather significantly.”

    In fact, some researchers have uncovered equivalent final results by combing through electronic information from health and fitness treatment suppliers in the U.S. That substantial review concluded that sufferers who had at the very least one particular vaccine dose ended up seven to 10 instances a lot less likely to report two or a lot more long COVID signs when compared to unvaccinated folks involving 12 and 20 weeks soon after their infection.

    On the other hand, the proof isn’t really solely conclusive. Some experiments have not observed as significant a reduction. For example, the preliminary findings of a key review of digital well being information of U.S. veterans analyzed the health-related difficulties influencing diverse organ units at 6 months pursuing coronavirus infection.

    Remaining thoroughly vaccinated did not show up to make a incredibly meaningful variance for several of the write-up-infection complications, besides in two specific regions, states the study’s creator Dr. Ziyad Al-Aly, director of clinical epidemiology at the Veterans Affairs St. Louis Overall health Care Procedure.

    Persons are acquiring less lingering manifestations in the lungs and also fewer blood clotting,” he suggests.

    The analyze also identified that those who were being hospitalized for COVID-19 experienced a larger threat of very long COVID symptoms compared with these who had a delicate illness, but that vaccines continued to make a significant variation in cutting down the danger of long COVID.

    “The vaccines are supposed to secure you from staying hospitalized,” suggests Al-Aly. “But even if they are unsuccessful and you get breakthrough COVID and now you might be hospitalized, you still do greater than somebody who got COVID and was in no way vaccinated.”

    Conflicting success in the scientific studies may perhaps, in section, be owing to how they are executed, this kind of as variances in the strategies of measuring extended COVID, how indications are noted and the affected person inhabitants currently being examined.

    A excellent shield — but not great

    Even with the promising proof, extended COVID scientists warning that vaccines can only do so significantly, and that invariably some individuals will continue to put up with signs even if they are vaccinated.

    In truth, a modern analyze from the U.K. observed that vaccines led to a significantly lessen hazard of extensive COVID as opposed with people who are unvaccinated, but that nevertheless close to 10{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of the absolutely vaccinated members showed indicators of lengthy COVID three months later on.

    David Putrino cares for extended COVID people who match this really profile at the Mount Sinai Wellbeing Procedure in New York Metropolis.

    “I don’t believe in fantastic religion I would be in a position to distinguish concerning another person who has a breakthrough scenario of extensive COVID versus a pre-vaccine case of prolonged COVID,” says Putrino, director of rehabilitation innovation at Mount Sinai. “The indications are extremely consistent.”

    And you will find now a further unresolved dilemma dealing with scientists: How properly do vaccines maintain up towards lengthy COVID just after an omicron infection?

    Mainly because omicron only emerged at the end of past 12 months, there are not nonetheless knowledge on how several folks have extensive COVID from the new variant, but Deeks states there are presently some individuals who seem to be heading in that way. “Without the need of issue, there are obviously men and women — I’m hoping not a ton — who acquired COVID a number of months back and are experience unwell right now,” he states.

    Centered on what is regarded about the variant, no one particular seriously understands for certain no matter if men and women who get omicron could be more, or significantly less, vulnerable to obtaining long COVID.

    On the just one hand, omicron is adept at evading the immune defenses set up by the vaccines, so it can be probable that “we could close up with much more extended COVID,” Deeks suggests.

    Alternatively, the variant sales opportunities to a extra localized an infection and won’t spread through the system as much, which implies there could essentially be fewer occasions of lengthy COVID.

    Deeks is leaning in direction of the a lot more optimistic circumstance. “That’s my prediction, but it truly is just a prediction.”

  • Anti-vaccine group uses telehealth to profit from unproven COVID-19 treatments : Shots

    Anti-vaccine group uses telehealth to profit from unproven COVID-19 treatments : Shots

    Ben Bergquam was hospitalized with COVID in January. He says he brought his own prescription for ivermectin — an unproven COVID therapy.

    Screenshot by NPR/Facebook


    hide caption

    toggle caption

    Screenshot by NPR/Facebook


    Ben Bergquam was hospitalized with COVID in January. He says he brought his own prescription for ivermectin — an unproven COVID therapy.

    Screenshot by NPR/Facebook

    Just before Christmas, a right-wing journalist named Ben Bergquam became seriously ill with COVID-19.

    “My Christmas gift was losing my [sense of] taste and smell and having a 105-degree fever, and just feeling like garbage,” Bergquam said in a Facebook video that he shot as he lay in a California hospital.

    “It’s scary. When you can’t breathe, it’s not a fun place to be,” he said.

    Bergquam told his audience he wasn’t vaccinated, despite having had childhood asthma, a potentially dangerous underlying condition. Instead, he held up a bottle of the drug ivermectin. Almost all doctors do not recommend taking ivermectin for COVID, but many individuals on the political right believe that it works.

    The details revealed in Bergquam’s video provide a rare view into the prescription of an unproven COVID-19 therapy. Data shows that prescriptions for drugs like ivermectin have surged in the pandemic, but patient-doctor confidentiality often obscures exactly who is handing out the drugs.

    Bergquam’s testimonial provides new and troubling details about a small group of physicians who are willing to eschew the best COVID-19 treatments and provide alternative therapies made popular by disinformation — for a price.

    Ivermectin is usually prescribed to treat parasitic worms, and the best medical evidence to date shows that it doesn’t work against COVID-19. The Food and Drug Administration, National Institutes of Health, American Medical Association and two pharmaceutical societies all discourage prescribing ivermectin for COVID-19, and many doctors and hospitals will not give it to patients who are seeking treatment.

    But fueled by conspiracy theories about vaccine safety and alternative treatments, many on the political right incorrectly believe ivermectin is a secret cure-all for COVID. As millions of Americans fell ill with COVID last summer, the Centers for Disease Control and Prevention reported ivermectin prescriptions were at 24 times pre-pandemic levels. The agency says prescriptions again rose during the latest omicron surge.

    A significant number of these prescriptions come from a small minority of doctors who are willing to write them, often using telemedicine to do so, according to Kolina Koltai, a misinformation researcher at the University of Washington. The same doctors frequently promote anti-vaccine conspiracy theories.

    “They’re profiting off misinformation, using their medical expertise as currency,” she says.

    A look into the world of unproven COVID treatments

    Bergquam told his audience he got his ivermectin from a group known as America’s Frontline Doctors. Their leader, Dr. Simone Gold, is currently facing multiple charges related to her role in the insurrection at the Capitol on Jan. 6, 2021. She is well known for spreading anti-vaccine propaganda, and she also tells audiences across the country to give her a call for prescriptions of unproven drugs like ivermectin. Her group charges $90 for the call, and Koltai believes the prescriptions are among its primary sources of income.

    “I would reckon that telehealth and telemedicine is one of the major income-generating streams for America’s Frontline Doctors,” she says.

    Last year, online publication The Intercept published a story based on hacked documents, which showed that the group was potentially making millions by selling thousands of prescriptions (Gold denies that story in public speeches, saying that the hack did not occur).

    In his video, Bergquam thanked the doctors repeatedly for prescribing him ivermectin. In doing so, he revealed the name of the licensed doctor writing the prescription: Kathleen Ann Cullen.

    Cullen, 54, is based out of Florida and has a troubling professional history. She spent most of last year under investigation by the state of Alabama, which eventually revoked her medical license in November, two months before Berquam entered the hospital. The cause was her involvement in a separate telemedicine company, according to E. Wilson Hunter, general counsel at the Alabama Board of Medical Examiners.

    “She was working with a telemedicine company and was utilizing her medical license to further their ability to generate billable events, without actually providing health care to the patients,” he says.

    In other words, Cullen was ordering a battery of expensive genetic tests remotely, without ever seeing or speaking to the patients she was testing. It was so bad, Hunter says, that she was ordering prostate cancer screenings for female patients, who do not have prostates.

    The company Cullen was working for at the time was called Bronson Medical LLC. It no longer has a functioning website, and its owner pleaded guilty in 2020 to federal health care fraud charges.

    When the Alabama board confronted Cullen, she failed to produce patient records.

    “At the hearing, she knew nothing, saw nothing, heard nothing, understood nothing and did not take responsibility for her actions,” Hunter says.

    These are not the only blemishes on her record. Cullen’s medical license in Kansas was suspended for failure to pay fees. And her American Board of Internal Medicine certification has lapsed (the board declined to say when the lapse occurred).

    In pandemic, dubious prescriptions continue

    Despite these problems, Cullen still has active medical licenses in North Carolina and Florida. It appears she is now using those medical licenses to prescribe ivermectin on behalf of America’s Frontline Doctors.

    In January, thousands of protesters gathered in Washington for a rally against vaccine mandates. Many believe in alternative therapies like ivermectin.

    Patrick Semansky/AP


    hide caption

    toggle caption

    Patrick Semansky/AP


    In January, thousands of protesters gathered in Washington for a rally against vaccine mandates. Many believe in alternative therapies like ivermectin.

    Patrick Semansky/AP

    “Where’s the accountability in all of that?” says Ashley Bartholomew, a nurse with No License For Disinformation, a group of medical professionals who are trying to force medical boards to take action in cases like these.

    Bartholomew was the first to notice Cullen’s name on the bottle. She said the entire video made her nervous because Ben Bergquam appeared to be bringing in his own outside medication to a hospital setting.

    “Is the nurse aware he’s also taking these prescribed medications from this doctor in Florida while he’s a hospitalized patient? And is his team of doctors aware? And is the pharmacy aware?” she asks.

    Even if they were, she worries the video — which has 23,000 views on Facebook — will encourage others to bring in outside meds, increasing their risk for complications.

    NPR contacted Bergquam, Cullen and America’s Frontline Doctors, and none provided comment for this article.

    As for the states where Cullen still holds a license, public records show the Florida Department of Health has filed two administrative complaints, but her license is listed as clear and active on their website. The department did not respond to repeated requests for comment. The North Carolina Medical Board meanwhile would not confirm whether an investigation was underway, but Brian Blankenship, the board’s deputy general counsel, says that investigations take time: “State Agencies have to give people due process rights based on evidence,” he says.

    “How many patients have to suffer?”

    Cullen’s case is somewhat unusual. The Federation of State Medical Boards says its data show that 94{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of doctors have licenses in just one or two states. The federation runs a database that helps notify states when disciplinary action is taken.

    “Within a day after cataloging and categorizing the disciplinary order, we’ll share with other states and territories,” says Humayun Chaudhry, the federation’s president.

    But often states must conduct their own, sometimes lengthy investigations. To streamline that process, Chaudhry says his organization is encouraging states to adopt a new Interstate Medical Licensure Compact that, when signed into law, would allow states to see when investigations are started against a physician. Although it would apply only for physicians who seek licensure through the compact.

    For Ashley Bartholomew, the nurse fighting disinformation, this case shows just how broken America’s medical licensing apparatus is. Cullen has already lost her license for poor telehealth practices, and yet, a tangle of state medical boards, laws and procedures continues to allow her to write prescriptions for questionable treatments.

    “How many patients have to suffer from disinformation,” Bartholomew asks, “until we actually have action?”

    NPR’s Sarah Knight contributed to this report.

  • Depression responds to transcranial magnetic stimulation treatment in studies : Shots

    Depression responds to transcranial magnetic stimulation treatment in studies : Shots

    Eleanor Cole, Ph.D., demonstrates the treatment on trial participant Deirdre Lehman in May 2019 at the Stanford Brain Stimulation Lab.

    Steve Fisch for Stanford Medicine


    hide caption

    toggle caption

    Steve Fisch for Stanford Medicine


    Eleanor Cole, Ph.D., demonstrates the treatment on trial participant Deirdre Lehman in May 2019 at the Stanford Brain Stimulation Lab.

    Steve Fisch for Stanford Medicine

    After 40 years of fighting debilitating depression, Emma was on the brink.

    “I was suicidal,” said Emma, a 59-year-old Bay Area resident. NPR is not using her full name at her request because of the stigma of mental illness. “I was going to die.”

    Over the years, Emma sat through hours of talk therapy and tried numerous anti-depression medications “to have a semblance of normalcy.” And yet she was consumed by relentless fatigue, insomnia and chronic nausea.

    Depression is the world’s leading cause of disability, partly because treatment options often result in numerous side effects or patients do not respond at all. And there are many people who never seek treatment because mental illness can carry heavy stigma and discrimination. Studies show untreated depression can lead to suicide.

    Three years ago, Emma’s psychiatrist urged her to enroll in a study at Stanford University School of Medicine designed for people who had run out of options. On her first day, scientists took an MRI scan to determine the best possible location to deliver electrical pulses to her brain. Then for a 10 minute block every hour for 10 hours a day for five consecutive days, Emma sat in a chair while a magnetic field stimulated her brain.

    At the end of the first day, an unfamiliar calm settled over Emma. Even when her partner picked her up to drive home, she stayed relaxed. “I’m usually hysterical,” she said. “All the time I’m grabbing things. I’m yelling, you know, ‘Did you see those lights?’ And while I rode home that first night I just looked out the window and I enjoyed the ride.”

    The remedy was a new type of repetitive transcranial magnetic stimulation (rTMS) called “Stanford neuromodulation therapy.” By adding imaging technology to the treatment and upping the dose of rTMS, scientists have developed an approach that’s more effective and works more than eight times faster than the current approved treatment.

    A coil placed on top of Emma’s head created a magnetic field that sent electric pulses through her skull to tickle the surface of her brain. She says it felt like a woodpecker tapping on her skull every 15 seconds. The electrical current is directed at the prefrontal cortex, which is the part of the brain that plans, dreams and controls our emotions.

    “It’s an area thought to be underactive in depression,” said Nolan Williams, a psychiatrist and rTMS researcher at Stanford. “We send a signal for the system to not only turn on, but to stay on and remember to stay on.”

    Williams says pumping up the prefrontal cortex helps turn down other areas of the brain that stimulate fear and anxiety. That’s the basic premise of rTMS: Electrical impulses are used to balance out erratic brain activity. As a result, people feel less depressed and more in control. All of this holds true in the new treatment — it just works faster.

    A recent randomized control trial, published in The American Journal of Psychiatry, shows impressive results are possible in five days of treatment or less. Almost 80{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of patients crossed into remission — meaning they were symptom-free within a month. This is compared to about 13{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of people who received the placebo treatment.

    For the control group, the researchers disguised the treatment with a magnetic coil that mimicked the actual treatment. Neither the scientist administering the procedure nor the patients knew if they were receiving the real or sham treatment. Patients did not report any serious side effects. The most common complaint was a light headache.

    Stanford’s new delivery system may even outperform electroconvulsive therapy, which is the most popular form of brain stimulation for depression, but while quicker, it requires general anesthesia.

    “This study not only showed some of the best remission rates we’ve ever seen in depression,” said Shan Siddiqi, a Harvard psychiatrist not connected to the study, “but also managed to do that in people who had already failed multiple other treatments.”

    Siddiqi also said the study’s small sample size, which is only 29 patients, is not cause for concern.

    “Often, a clinical trial will be terminated early [according to pre-specified criteria] because the treatment is so effective that it would be unethical to continue giving people placebo,” said Siddiqi. “That’s what happened here. They’d originally planned to recruit a much larger sample, but the interim analysis was definitive.”

    Nolan Williams demonstrates the magnetic brain stimulation therapy he and his colleagues developed, on Deirdre Lehman, a participant in a previous study of the treatment.

    Steve Fisch for Stanford Medicine


    hide caption

    toggle caption

    Steve Fisch for Stanford Medicine


    Nolan Williams demonstrates the magnetic brain stimulation therapy he and his colleagues developed, on Deirdre Lehman, a participant in a previous study of the treatment.

    Steve Fisch for Stanford Medicine

    Mark George, a psychiatrist and neurologist at the Medical University of South Carolina, agrees. He points to other similarly sized trials for depression treatments like ketamine, a version of which is now FDA-approved.

    He says the new rTMS approach could be a game changer because it’s both more precise and kicks in faster than older versions. George pioneered an rTMS treatment that was approved by the federal Food and Drug Administration for depression in 2008. Studies show that it produces a near total loss of symptoms in about a third of patients; another third feel somewhat better and another third do not respond at all. But the main problem with the original treatment is that it takes six weeks, which is a long time for a patient in the midst of a crisis.

    “This study shows that you can speed it all up and that you can add treatments in a given day and it works,” said George.

    The shorter treatment will increase access for a lot of people who cannot get six weeks off work or cover child care for that long.

    “The more exciting applications, however, are due to the rapidity,” said George. “These people [the patients] got unsuicidal and undepressed within a week. Those patients are just clogging up our emergency rooms, our psych hospitals. And we really don’t have good treatments for acute suicidality.”

    After 45 years of depression and numerous failed attempts to medicate his illness, Tommy Van Brocklin, a civil engineer, says he didn’t see a way out.

    “The past couple of years I just started crying a lot,” he said. “I was just a real emotional wreck.”

    So last September, Van Brocklin flew across the country from his home in Tennessee to Stanford, where he underwent the new rTMS treatment for a single five-day treatment. Almost immediately he started feeling more optimistic and sleeping longer and deeper.

    “I wake up now and I want to come to work, whereas before I’d rather stick a sharp stick in my eye,” said Van Brocklin. “I have not had any depressed days since my treatment.”

    He is hopeful the changes stick. More larger studies are needed to verify how long the new rTMS treatment will last.

    At least for Emma, the woman who received Stanford’s treatment three years ago in a similar study, the results are holding. She says she still has ups and downs but “it’s an entirely different me dealing with it.”

    She says the regimen rewired her from the inside out. “It saved my life, and I’ll be forever grateful,” said Emma over the phone, her voice cracking with emotion. “It saved my life.”

    Stanford’s neuromodulation therapy could be widely available by the end of this year — that’s when scientists are hoping FDA clearance comes through. The technology is licensed to Magnus Medical, a startup with plans to commercialize it

    Williams, the lead researcher at Stanford, says he’s optimistic insurance companies will eventually cover the new delivery model because it works in a matter of days, so it’s likely more cost-effective than a conventional 6 week rTMS regimen. Major insurance companies and Medicare currently cover rTMS, though some plans require patients to demonstrate that they’ve exhausted other treatment options.

    The next step is studying how rTMS may improve other mental health disorders like addiction and traumatic brain injury.

    “This study is hopefully just the tip of the iceberg,” said Siddiqi. “I think we’re finally on the verge of a paradigm shift in how we think about psychiatric treatment, where we’ll supplement the conventional chemical imbalance and psychological conflict models with a new brain circuit model.”

    In other words, electricity in the form of rTMS could become one of the vital tools used to help people with mental illness.